Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker ANRO
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 10, 2026 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 27, 2026 | ANRO Alto Neuroscience, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 12, 2026 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 14, 2026 | ANRO Alto Neuroscience, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jul 13, 2026 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jul 13, 2026 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 28, 2026 | ANRO Alto Neuroscience, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 13, 2026 | ANRO Alto Neuroscience, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 13, 2026 | ANRO Alto Neuroscience, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 13, 2026 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 1, 2026 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Mar 16, 2026 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 16, 2026 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Mar 16, 2026 | ANRO Alto Neuroscience, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Mar 16, 2026 | ANRO Alto Neuroscience, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 12, 2025 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Oct 20, 2025 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Oct 20, 2025 | ANRO Alto Neuroscience, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Oct 20, 2025 | ANRO Alto Neuroscience, Inc. | 1.02 Termination of a Material Definitive Agreement | 8-K | 8-K ↗ |
| Oct 20, 2025 | ANRO Alto Neuroscience, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 13, 2025 | ANRO Alto Neuroscience, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 13, 2025 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 8, 2025 | ANRO Alto Neuroscience, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jun 26, 2025 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 3, 2025 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 3, 2025 | ANRO Alto Neuroscience, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jun 3, 2025 | ANRO Alto Neuroscience, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 14, 2025 | ANRO Alto Neuroscience, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 14, 2025 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 20, 2025 | ANRO Alto Neuroscience, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 20, 2025 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 12, 2025 | ANRO Alto Neuroscience, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Feb 3, 2025 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 3, 2025 | ANRO Alto Neuroscience, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jan 16, 2025 | ANRO Alto Neuroscience, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Jan 16, 2025 | ANRO Alto Neuroscience, Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Jan 16, 2025 | ANRO Alto Neuroscience, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 12, 2024 | ANRO Alto Neuroscience, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
38 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:52 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances